A phase I study of AT7519M given twice weekly in patients with advanced incurable malignancy.
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2016
At a glance
- Drugs AT 7519 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 21 Sep 2011 Planned End Date changed from 1 Oct 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 27 Apr 2011 Actual end date changed from 1 Aug 2009 to 4 Apr 2011 as reported by National Cancer Institute of Canada.
- 11 Nov 2010 Status changed from recruiting to completed. This trial has recently been completed in 29 patients according to an Astex Therapeutics media release.